AB0471 PATIENTS WITH RADIOGRAPHIC axSpA WHO PROGRESSED FROM ASAS20 AT WEEK 16 TO ASAS40 AT WEEK 52: RESULTS FROM COAST-W

Background: The timeframe for maximum treatment response varies across patients with radiographic axial spondyloarthritis (r-axSpA). Understanding which may benefit from additional time on could influence decisions. Objectives: This post-hoc analysis aims to determine the percentage of patients, previously exposed TNFi, who progressed ASAS20 at week 16 ASAS40 52 ixekizumab (IXE) and explore factors that associate improvement after weeks. Methods: Patients achieved Assessment SpondyloArthritis International Society (ASAS)20 COAST-W ( NCT02696798 ), a Phase 3, randomized, double-blind, placebo-controlled trial, in tumour necrosis factor inhibitor (TNFi)-experienced fulfilled ASAS criteria r-axSpA, were analysed. treated IXE 80 mg Q4W categorized according their 52: sustaining but not reaching an or achieving ASAS40. Patient demographics disease characteristics baseline analysed by descriptive statistics, individual components determining are provided. Results: At 16, 22.8% (n=26/114) ASAS40; these, 2 discontinued study before 52. Amongst continued through 52, 50% (12/24) other sustained response. older, had longer duration, less likely be HLA-B27 positive, worse BASDAI BASFI scores (Table 1, part a). Achieving appeared depend most Global Disease Activity spinal pain score over b). Table 1. a) Demographics Characteristics Baseline (week 0) b) Descriptive observed data mean (SD) IXEQ4W (n=12) Age, years 47.3 (13.3) 49.6 (12.3) Duration symptoms since axSpA onset, 16.4 (9.2) 18.6 (12.6) HLA B27 n (%) 12 (100) 9 (75) Current tobacco use, 4 (33.3) 1 (8.3) ASDAS Score 4.0 (1.0) 4.2 (1.1) 7.4 (1.2) 7.8 (1.7) Serum CRP concentration (mg/L) 23.0 (47.1) 28.0 (66.0) Spinal Pain due Ankylosing Spondylitis (NRS) 8.2 (0.8) 8.5 (1.6) (1.3) 8.6 7.1 (1.4) (2.3) stiffness (1.5) 7.6 (2.2) b ) 5.5 (1) 3.2 5.6 3 (1.9) 5.0 3.7 (2.1) 4.1 3.4 Values unless stated otherwise ASAS= Society; ASDAS= Score; axSpa = spondyloarthritis; BASDAI= Bath Index; BASFI= Functional CRP= C-reactive protein; HLA= human leucocyte antigen; NRS numeric rating scale; SD= standard deviation Conclusion: For r-axSpA TNFis showing modest weeks, exposure required achieve Acknowledgements: authors would like acknowledge Philana Fernandes, employee Eli Lilly, her editorial writing support. Disclosure Interests: Xenofon Baraliakos Speakers bureau: Abbvie, BMS, Chugai, Celgene, Pfizer, Galapagos, UCB, MSD, Consultant of: Grant/research support from: Atul Deodhar AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Giliad, GlaxoSmith & Kline, Janssen, Novartis, Soyi Liu Leage Employee Yves Schymura Rebecca Bolce Shareholder David Sandoval Jessica A. Walsh Amgen Merck, Joachim Sieper Lilly Novartis.